Treatment of recurrent respiratory papillomatosis and adverse reactions following off-label use of cidofovir (Vistide®).
Robin E A
RE
Tjon Pian Gi
Andreas
A
Dietz
Vojko
V
Djukic
Hans E
HE
Eckel
Gerhard
G
Friedrich
Wojciech
W
Golusinski
Anastasios
A
Hantzakos
George
G
Lawson
Marc
M
Remacle
Heikki
H
Rihkanen
Frederik G
FG
Dikkers
D016907:Adverse Drug Reaction Reporting Systems; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000077404:Cidofovir; D003596:Cytosine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D015552:Injections, Intralesional; D009369:Neoplasms / Q000139:chemically induced; D009503:Neutropenia / Q000139:chemically induced; D056687:Off-Label Use; D063065:Organophosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D010212:Papilloma / Q000188:drug therapy*; D030361:Papillomavirus Infections / Q000188:drug therapy*; D012008:Recurrence; D051437:Renal Insufficiency / Q000139:chemically induced; D012141:Respiratory Tract Infections / Q000188:drug therapy*
D000998:Antiviral Agents; D063065:Organophosphonates; D003596:Cytosine; D000077404:Cidofovir